|
Evaluation of the Interaction Between Acetaminophen and Zidovudine Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified health advice, travels to or treatment by using a genuine physician. We are not physicians. Always consult your dr. on Evaluation of the Interaction Between Acetaminophen and Zidovudine conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Evaluation of the Interaction Between Acetaminophen and Zidovudine Clinical research trials and Evaluation of the Interaction Between Acetaminophen and Zidovudine health trials occur in hundreds of cities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new drugs. The propose of the studies / undertakings is to resolve certain human health questions. Clinical trials are a popular means for physicians, government agencies, and private sector companies to locate treatments for all sorts of conditions, including Evaluation of the Interaction Between Acetaminophen and Zidovudine. Evaluation of the Interaction Between Acetaminophen and Zidovudine Clinical Trials and other clinical trials permit volunteers to acquire medical treatment choices before they are available to the masses. Some times the test subjects obtain professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Evaluation of the Interaction Between Acetaminophen and Zidovudine clinical trial. Participants oftentimes recieve the most expert healthcare available for their Evaluation of the Interaction Between Acetaminophen and Zidovudine condition. Hazards are a reality, however, and can include extra or frequent physician visits, health risks (potentially life-endangering), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Evaluation of the Interaction Between Acetaminophen and Zidovudine  Evaluation of the Interaction Between Acetaminophen and Zidovudine
Evaluation of the Interaction Between Acetaminophen and Zidovudine
For Condition: HIV Infections
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: To determine if zidovudine (AZT) and acetaminophen (APAP) interact when given to the same patient, and if so, the manner of interaction. Patients with AIDS often require therapy with painkillers for the management of mild pain and discomfort associated with their disease, and APAP is often prescribed. AZT is being used to treat AIDS patients. It is important for doctors to understand how AZT and APAP may interact when given to the same patient, because other studies have suggested that the dosage of AZT may have to be adjusted when given with APAP in order to avoid or minimize adverse effects.
Details: Patients with AIDS often require therapy with painkillers for the management of mild pain and discomfort associated with their disease, and APAP is often prescribed. AZT is being used to treat AIDS patients. It is important for doctors to understand how AZT and APAP may interact when given to the same patient, because other studies have suggested that the dosage of AZT may have to be adjusted when given with APAP in order to avoid or minimize adverse effects. Persons who are infected with HIV and have symptoms (fever, fatigue, weight loss) of AIDS are eligible for the study. They will be given AZT orally every 4 hours or APAP orally every 8 hours alone or in combination for 4 days while at home. On the 4th day, participants will be admitted to a clinical research center for studies to determine how they are tolerating the medicine. On the 5th day, any scheduled 8 am doses of AZT will be given intravenously, while the scheduled doses of APAP will still be given orally. Repeated blood samples will be taken over the next 12 hours and urine will be collected for 24 hours. The process will be repeated at weekly intervals for 3 weeks, so that each patient receives AZT alone, APAP alone, and the combination of AZT and APAP.
Eligibility:
Study Type: Interventional, Treatment, Open Label, Pharmacokinetics Study
Minimum Age/Maximum Age: 18 Years/50 Years
Genders: Both
Protocol Entry Criteria: Exclusion Criteria Co-existing Condition: Patients with the following are excluded: - Severe ongoing opportunistic infection including Pneumocystis carinii pneumonia (PCP), cryptococcal or toxoplasmosis meningoencephalitis, disseminated herpes simplex or herpes zoster. A demonstrated prior sensitivity or an experience of significant adverse effects during prior therapy with the drug to be used in the study. - Significant diarrhea at entry ( > 1 watery stool/day). Patients with the following are excluded: - Severe ongoing opportunistic infection including Pneumocystis carinii pneumonia (PCP), cryptococcal or toxoplasmosis meningoencephalitis, disseminated herpes simplex or herpes zoster. A demonstrated prior sensitivity or an experience of significant adverse effects during prior therapy with the drug to be used in the study. - Significant diarrhea at entry ( > 1 watery stool/day). AIDS related complex (ARC) defined as presence of any one of the following within 12 months prior to entry and absence of a concurrent illness or condition other than HIV infection to explain the findings: - Fever of > 38.5 degrees C persisting for longer than 3 weeks. - Involuntary weight loss of > 15 lbs. or > 10 percent of baseline noted in a 120-day period prior to evaluation. - History of diarrhea (> 2 liquid stools per day) persisting for longer than 1 month but not occurring at entry. - History of clinical diagnosis of oral candidiasis or hairy leukoplakia. Patients who have AIDS-defined opportunistic infections or tumors. - Patients eligible for zidovudine under the labeling. A positive HIV antibody test. Exceptions will be made for patients with a previously positive HIV antibody test with progressive disease and patients where virus isolation has been made. A life expectancy of at least 3 months. - Patients with stable Kaposi's sarcoma, mild herpes infections, mild or stable depression, asymptomatic or mild cytomegalovirus or Epstein-Barr virus infection, or a hepatitis B virus carrier state will be acceptable for study. Inability to abstain from alcohol or any other drug, including nonprescription medications, during the study period.
Total Enrollment: 10
Location and Contact Information:
Overall Study Official:
PtachcinskiR, Study Chair,
Univ of Pittsburgh Med School
Pittsburgh, Pennsylvania,
United States
Additional Information:
Study ID Numbers: ACTG 032;
Study Start Date:
Record last reviewed: October 1991
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00000731
Other Hiv Infections Studies:
1. A Study of the Safety and Effectiveness of Different Doses of 1592U89 in HIV-Infected Patients
2. Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients
3. Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand
4. A Study to Evaluate the Effects of Stopping Maintenance Therapy for Cytomegalovirus (CMV) Retinitis after Effective Anti-HIV Therapy
5. Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Patients Following Failure with Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART
Related Studies:
Other HIV Infections Clinical Trials
Other Pennsylvania Clinical Trials
Other Pittsburgh Clinical Trials
Evaluation of the Interaction Between Acetaminophen and Zidovudine
|
|
|
|
|
|
|
|
